Cargando…

Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with high mutational heterogeneity and a generally poor clinical outcome. Despite implicated roles of deregulated TP53, IGF-2 and Wnt signaling pathways, a clear genetic association or unique mutational link to the disease is...

Descripción completa

Detalles Bibliográficos
Autores principales: Korah, Reju, Healy, James M, Kunstman, John W, Fonseca, Annabelle L, Ameri, Amir H, Prasad, Manju L, Carling, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750604/
https://www.ncbi.nlm.nih.gov/pubmed/23915220
http://dx.doi.org/10.1186/1476-4598-12-87
_version_ 1782281451816878080
author Korah, Reju
Healy, James M
Kunstman, John W
Fonseca, Annabelle L
Ameri, Amir H
Prasad, Manju L
Carling, Tobias
author_facet Korah, Reju
Healy, James M
Kunstman, John W
Fonseca, Annabelle L
Ameri, Amir H
Prasad, Manju L
Carling, Tobias
author_sort Korah, Reju
collection PubMed
description BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with high mutational heterogeneity and a generally poor clinical outcome. Despite implicated roles of deregulated TP53, IGF-2 and Wnt signaling pathways, a clear genetic association or unique mutational link to the disease is still missing. Recent studies suggest a crucial role for epigenetic modifications in the genesis and/or progression of ACC. This study specifically evaluates the potential role of epigenetic silencing of RASSF1A, the most commonly silenced tumor suppressor gene, in adrenocortical malignancy. RESULTS: Using adrenocortical tumor and normal tissue specimens, we show a significant reduction in expression of RASSF1A mRNA and protein in ACC. Methylation-sensitive and -dependent restriction enzyme based PCR assays revealed significant DNA hypermethylation of the RASSF1A promoter, suggesting an epigenetic mechanism for RASSF1A silencing in ACC. Conversely, the RASSF1A promoter methylation profile in benign adrenocortical adenomas (ACAs) was found to be very similar to that found in normal adrenal cortex. Enforced expression of ectopic RASSF1A in the SW-13 ACC cell line reduced the overall malignant behavior of the cells, which included impairment of invasion through the basement membrane, cell motility, and solitary cell survival and growth. On the other hand, expression of RASSF1A/A133S, a loss-of-function mutant form of RASSF1A, failed to elicit similar malignancy-suppressing responses in ACC cells. Moreover, association of RASSF1A with the cytoskeleton in RASSF1A-expressing ACC cells and normal adrenal cortex suggests a role for RASSF1A in modulating microtubule dynamics in the adrenal cortex, and thereby potentially blocking malignant progression. CONCLUSIONS: Downregulation of RASSF1A via promoter hypermethylation may play a role in the malignant progression of adrenocortical carcinoma possibly by abrogating differentiation-promoting RASSF1A- microtubule interactions.
format Online
Article
Text
id pubmed-3750604
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37506042013-08-24 Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma Korah, Reju Healy, James M Kunstman, John W Fonseca, Annabelle L Ameri, Amir H Prasad, Manju L Carling, Tobias Mol Cancer Research BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with high mutational heterogeneity and a generally poor clinical outcome. Despite implicated roles of deregulated TP53, IGF-2 and Wnt signaling pathways, a clear genetic association or unique mutational link to the disease is still missing. Recent studies suggest a crucial role for epigenetic modifications in the genesis and/or progression of ACC. This study specifically evaluates the potential role of epigenetic silencing of RASSF1A, the most commonly silenced tumor suppressor gene, in adrenocortical malignancy. RESULTS: Using adrenocortical tumor and normal tissue specimens, we show a significant reduction in expression of RASSF1A mRNA and protein in ACC. Methylation-sensitive and -dependent restriction enzyme based PCR assays revealed significant DNA hypermethylation of the RASSF1A promoter, suggesting an epigenetic mechanism for RASSF1A silencing in ACC. Conversely, the RASSF1A promoter methylation profile in benign adrenocortical adenomas (ACAs) was found to be very similar to that found in normal adrenal cortex. Enforced expression of ectopic RASSF1A in the SW-13 ACC cell line reduced the overall malignant behavior of the cells, which included impairment of invasion through the basement membrane, cell motility, and solitary cell survival and growth. On the other hand, expression of RASSF1A/A133S, a loss-of-function mutant form of RASSF1A, failed to elicit similar malignancy-suppressing responses in ACC cells. Moreover, association of RASSF1A with the cytoskeleton in RASSF1A-expressing ACC cells and normal adrenal cortex suggests a role for RASSF1A in modulating microtubule dynamics in the adrenal cortex, and thereby potentially blocking malignant progression. CONCLUSIONS: Downregulation of RASSF1A via promoter hypermethylation may play a role in the malignant progression of adrenocortical carcinoma possibly by abrogating differentiation-promoting RASSF1A- microtubule interactions. BioMed Central 2013-08-05 /pmc/articles/PMC3750604/ /pubmed/23915220 http://dx.doi.org/10.1186/1476-4598-12-87 Text en Copyright © 2013 Korah et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Korah, Reju
Healy, James M
Kunstman, John W
Fonseca, Annabelle L
Ameri, Amir H
Prasad, Manju L
Carling, Tobias
Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
title Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
title_full Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
title_fullStr Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
title_full_unstemmed Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
title_short Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
title_sort epigenetic silencing of rassf1a deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750604/
https://www.ncbi.nlm.nih.gov/pubmed/23915220
http://dx.doi.org/10.1186/1476-4598-12-87
work_keys_str_mv AT korahreju epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma
AT healyjamesm epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma
AT kunstmanjohnw epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma
AT fonsecaannabellel epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma
AT ameriamirh epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma
AT prasadmanjul epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma
AT carlingtobias epigeneticsilencingofrassf1aderegulatescytoskeletonandpromotesmalignantbehaviorofadrenocorticalcarcinoma